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Abstract
Background: Subjects born with low birth weight (LBW) display a more energy-conserving response to fasting
compared with normal birth weight (NBW) subjects. However, the molecular mechanisms explaining these
metabolic differences remain unknown. Environmental influences may dynamically affect epigenetic marks, also in
postnatal life. Here, we aimed to study the effects of short-term fasting on leptin (LEP) and adiponectin (ADIPOQ)
DNA methylation and gene expression in subcutaneous adipose tissue (SAT) from subjects with LBW and NBW.
Methods: Twenty-one young LBW men and 18 matched NBW controls were studied during 36 h fasting. Eight
subjects from each group completed a control study (overnight fast). We analyzed SAT LEP and ADIPOQ
methylation (Epityper MassARRAY), gene expression (q-PCR), and adipokine plasma levels.
Results: After overnight fast (control study), LEP and ADIPOQ DNA methylation levels were higher in LBW compared
to those in NBW subjects (p ≤ 0.03) and increased with 36 h fasting in NBW subjects only (p ≤ 0.06). Both LEP and
ADIPOQ methylation levels were positively associated with total body fat percentage (p ≤ 0.05). Plasma leptin levels
were higher in LBW versus NBW subjects after overnight fasting (p = 0.04) and decreased more than threefold in
both groups after 36 h fasting (p ≤ 0.0001).
Conclusions: This is the first study to demonstrate that fasting induces changes in DNA methylation. This was
shown in LEP and ADIPOQ promoters in SAT among NBW but not LBW subjects. The altered epigenetic flexibility in
LBW subjects might contribute to their differential response to fasting, adipokine levels, and increased risk of
metabolic disease.
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Background
DNA methylation is the most studied epigenetic feature
and was initially considered to be mitotically stable. How-
ever, today we experience an increasing understanding of
environmental regulation of DNA methylation in adult life,
and recent studies have shown that ageing [1–3], exercise
[4, 5], and dietary factors [6–9] can alter site-specific DNA
methylation in humans, across different tissues. Epigenetic
modifications have further been associated with differential
gene expression and altered metabolism in key diabetic
tissues, including adipose tissue [4, 10–12].
Adipose tissue regulates energy homeostasis by storing
lipids and secreting adipokines, and dysregulation of
adipokine secretion has been shown to be directly
involved in the pathophysiology of the metabolic syn-
drome [13, 14]. The most important adipokines include
leptin, a key hormone regulating satiety that show a high
correlation between adipose tissue mass and plasma
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levels [15] and adiponectin, an important regulator of
glucose and lipid metabolism, which, in spite of its ex-
clusive secretion from adipose tissue, shows a negative
correlation with visceral adiposity [16].
Type 2 diabetes (T2D) and obesity are complex and
multi-factorial diseases with an etiology dependent upon
both genetic and environmental factors, where also the
prenatal environment may play an important role [17].
The establishment of epigenetic modifications during fetal
development is dependent on maternal lifestyle [18], pla-
cental function, and nutrient supply [19] and may link an
adverse prenatal environment with higher risk of develop-
ing metabolic diseases in postnatal life [20, 21]. Being born
with low birth weight (LBW) has been confirmed in
several human studies to be associated with increased risk
of developing insulin resistance and T2D in adult life
[22–24]. In this regard, several studies have reported
alterations of epigenetic patterns and plasticity in hu-
man tissues that are relevant to metabolic diseases in
subjects born at term with a LBW compared to
normal birth weight (NBW) subjects [6, 8, 9, 25].
LBW individuals have been characterized with in-
creased total [23] and abdominal [6] fat mass in early
adulthood compared to NBW individuals. Previously, we
have found that when exposed to high-fat overfeeding,
young LBW men respond with less increase in fasting
plasma leptin (p-leptin) levels compared to NBW sub-
jects [26]. This suggests an impaired regulation of leptin
secretion and/or expression among LBW subjects. Add-
itionally, we recently showed that LBW subjects display
a more energy-conserving response to fasting compared
with NBW subjects [27]. However, whether adipokine
dysregulation is involved in development of metabolic
diseases among LBW subjects and, importantly by which
mechanisms, remains to be elucidated.
To our knowledge, the effects of fasting on DNA
methylation have not been examined previously. In the
present study, we investigated whether DNA methyla-
tion and expression of LEP and ADIPOQ were affected
by 36 h fasting, in subcutaneous adipose tissue (SAT)
from young, healthy NBW and LBW men.
Methods
Study design
As previously published [27], 21 LBW and 18 NBW sub-
jects were recruited from the Danish National Birth
Registry according to LBW (birth weight ≤10th percent-
ile) or NBW (50th percentile ≤ birth weight ≤ 75th
percentile). All participants were born at term (week
39–41) and were matched as healthy, non-diabetic,
young males, with no history of diabetes in two genera-
tions and with a BMI <30 kg/m2. All participants were
subjected to 36 h fasting, and after 8–16 weeks, 7 LBW
and 6 NBW subjects were examined again during a
control study, conducted through a 36-h period where
the subjects received a diet equal to the standardization
meals, and where biopsies were excised after an over-
night (12 h) fast. Furthermore, 1 LBW and 2 NBW sub-
jects returned after 3 days of standardization by control
diet, only to participate by collection of overnight fasting
samples (12 h) and tissue biopsies as described below.
Thus, control study samples were obtained after an over-
night fast from a total of 8 LBW and 8 NBW subjects
who all also participated in the 36-h fasting study.
For 72 h prior to the fasting or control study interven-
tions, the participants received a control diet of pre-
cooked meals to achieve standardization of energy
intake (10 MJ per day, 50% carbohydrate, 35% fat, 15%
protein). In addition the participants were not allowed
to perform exercise or consume alcohol or soft drinks in
these 3 days. During both the fasting and control study,
the participants were allowed ad libitum water.
Clinical examinations
The fasting intervention study and the control study
were performed with identical study settings and activ-
ities, carried out over 3 days (Fig. 1). The participants ar-
rived at Steno Diabetes Center at 7.30 p.m., where they
received a meal. In the fasting study, finishing of the
meal marked the beginning of the fasting period. The
next day (day 1), a catheter was placed in the subjects’
left arm and blood sampling began at 8.00 a.m. During
day 1, anthropometric measurements of weight, height,
BMI, and waist-hip ratio were obtained and dual-energy
X-ray absorptiometry (DXA) scanning (Hologic Discov-
ery QDR Series) was performed for determination of
body composition. Furthermore, the participants had
two periods of light exercise to avoid inactivity. On day
2, after 36 h fasting, between 7.00 and 7.30 a.m., abdom-
inal SAT biopsies were obtained using a Bergström
needle under suction and under local anesthesia by
Xylocain (AstraZeneca). Immediately biopsies were fro-
zen in liquid nitrogen and stored at −80 °C. At 8.00 a.m.,
an Intravenous Glucose Tolerance Test (IVGTT) was
initiated (ending the fasting period), and at 11.00 a.m.,
the participant received a standardized test meal, which
should be consumed within 15 min.
In brief, LBW subjects were characterized by a shorter
height (p = 0.01) and lower lean body mass (p < 0.03),
but with similar fat mass, total body fat percentage
(BF%), BMI, and metabolic markers as NBW subjects. In
both groups, the fasting intervention increased free fatty
acid levels and reduced the clearance of p-glucose
during the IVGTT, most likely due to development of
peripheral insulin resistance as a consequence of fasting.
Furthermore, we found that LBW subjects had a more
pronounced decrease in s-insulin and triglyceride levels
and exhibited a decrease of the total rate of energy
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expenditure during fasting which increased among
NBW subjects. These data have previously been reported
in more detail [27] and are summarized in Table 1.
Intravenous glucose tolerance test
For evaluation of in vivo beta cell function, an intravenous
glucose tolerance test (IVGTT) was conducted. A dose of
0.3 g glucose/kg body weight was infused and caused a
first-phase insulin response (FPIR), which peaked within 2–
5 min and lasted approximately 10 min. Twenty minutes
after administration of the glucose dose, an IV insulin bolus
of 0.02 IU insulin/kg (Actrapid®, Novo Nordisk) was in-
fused. The IVGTT assessment and the calculations of insu-
lin sensitivity have been described in detail previously [27].
Blood sampling and biomarker analysis
All plasma samples were immediately distributed into
tubes, placed on ice, and centrifuged at 3000 rpm for
15 min (Eppendorf Centrifuge 5810R, Eppendorf AG,
Hamburg, Germany). Plasma and serum were obtained
and stored at −80 °C for later analysis. Blood sampling for
plasma leptin and adiponectin (p-leptin, p-adiponectin)
was performed immediately after 12 and 36 h of both the
fasting and control study, 3 h after initiation of the
IVGTT, and 3 h after the meal test (Fig. 1).
Plasma adiponectin and leptin were determined by vali-
dated, in-house, monoclonal immunoassays, based on
commercial reagents from Bio-Techne (Abingdon, UK).
The assays were performed without any pre-treatment of
samples prior to assay apart from appropriate dilution.
Adiponectin was determined using MAB 10651 for coat-
ing and BAM 1065 for detection, leptin was determined
using MAB 398 for coating and BAM 398 for detection.
Recombinant proteins served as assay calibrators. All
samples were assayed in duplicates, with intra-assay coeffi-
cients of variation (CV) of unknown samples <5% and
inter-assay CVs of control samples <10% [28, 29]. All
concentrations below the lower limit of detection (the
non-specific binding control plus three standard devia-
tions (SD)) were arbitrarily set at 0.1 μg/L for p-leptin,
and 0.1 mg/L for p-adiponectin (total).
DNA methylation analyses
Genomic DNA was extracted from SAT biopsies using
the QIAamp DNA Mini Kit (Qiagen, Valencia, CA,
USA). To quantify DNA methylation of LEP and ADI-
POQ, Sequenom’s MassARRAY EpiTYPER protocol was
applied (Sequenom, San Diego, CA, USA). Assays were
designed using EpiDesigner (Sequenom). The human
LEP promoter contains a CpG island that is associated
with demethylation during adipocyte differentiation [30];
hence, we aimed to study DNA methylation in this re-
gion. Two EpiTYPER assays were designed to cover the
LEP proximal promoter region, including 57 CpG sites.
Due to either low or high mass of the DNA cleavage
lengths, in total 39 CpG sites generated measurable
DNA methylation data (Fig. 2a). A proximal ADIPOQ
promoter region has been shown to be sufficient for
basal transcriptional activity [31], and additionally, a
distal enhancer region has also been shown to affect adi-
ponectin promoter activity [32]. Hence, one assay was
designed in the enhancer region and one assay in the
proximal promoter, covering in total 10 measurable CpG
sites (Fig. 2b). Primer sequences are shown in Additional
file 1: Table S1. Due to base-specific cleavage, several
CpG sites were analyzed as units, as indicated in Fig. 2.
Genomic DNA (400 ng) from adipose tissue was bisul-
fite converted using the high-throughput EZ-96 DNA
Fig. 1 Study design. Overview of the study activities and time periods of fasting shown in both the fasting study and the control study. 21 LBW and
18 NBW men participated in the 36-h fasting study intervention. A subset of 7 LBW and 6 NBW men from the 36-h fasting study also participated in
the control study intervention. Further 1 LBW and 2 NBW men also participated in the control study only with biopsy collections. Abbreviations: LBW
low birth weight, NBW normal birth weight, DXA scan dual-energy X-ray absorptiometry scan, IVGTT intravenous glucose tolerance test
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Methylation Kit (ZYMO Research, Orange, CA, USA).
Bisulfite-specific primers (Additional file 1: Table S1) were
used to generate PCR amplicons. The PCR amplicons
were then processed using the MassCleave (hMC) kit. The
reverse transcribed cleavage products were dispensed onto
a 384 element SpectroCHIP bioarray and using the Mas-
sARRAY mass spectrometer (Sequenom), mass spectra
were obtained and DNA methylation ratios were analyzed
by the EpiTYPER software v.1.0.1 (Sequenom).
Gene expression
The miRNeasy Mini Kit (Qiagen) was used for total RNA
extraction. cDNA synthesis was performed with the
QuantiTect Reverse Transcription Kit (Qiagen). Messen-
ger RNA (mRNA) expression of LEP, ADIPOQ and the
reference gene cyclophilin A (PPIA) was measured by
quantitative real-time PCR (q-PCR) using the ABI PRISM
7900HT Sequence Detection System (Applied Biosystems)
and assays-on-design for LEP (Hs00174877_m1*, FAM-
labelled), ADIPOQ (Hs00605917_m1*, FAM-labelled), and
PPIA (43263116E, VIC-labelled) (all Applied Biosystems).
The standard curve principal was applied for gene expres-
sion quantification and samples were normalized to PPIA.
Birth weight and fasting did not affect the expression of
PPIA (Additional file 2: Figure S1).
Statistical methodology
Analyses for parametric data were performed using the
paired and unpaired Student t test and analyses of non-
parametrically distributed data were performed using the
Wilcoxon test for paired data and the Mann-Whitney
U-test for unpaired data. Correlation analyses were
performed using the Pearson correlation test for para-
metric data and Spearman rank correlation test for non-
parametric data. A mixed effects model was applied to
analyze the repeated measurements of p-leptin and p-
adiponectin at all four time points of collection under
the choice of an unstructured correlation model accord-
ing to the structure of data, the distribution of the re-
sidual variances and the number of parameters involved.
Table 1 Clinical characteristics of the study participants
LBW NBW p value
N = 21 N = 18
At baseline
Birth weight (g) 2811 (205) 3643 (185) <0.0001
Gestational age (weeks) 40 (0.9) 39.9 (0.7) 0.83
Age (years) 24.8 (1.4) 24.6 (1.2) 0.65
Height (cm) 180.7 (5.7) 185.3 (5.3) 0.01
Weight (kg) 73.5 (10) 78.5 (10.7) 0.14
BMI (kg/m2) 22.5 (2.6) 22.9 (3.2) 0.65
W/H ratio 0.9 (0.07) 0.89 (0.05) 0.76
Subtotal fat (kg) 12.2 (5.2) 12.4 (5.4) 0.90
Subtotal fat (%) 17.1 (5.2) 16.3 (5.1) 0.61
Subtotal lean (kg) 54.6 (5.8) 59.2 (6.7) 0.03
HgbA1c (%) 5.1 (0.3) 5.1 (0.2) 0.87
Total cholesterol (mmol/L) 4.0 (0.6) 4.3 (0.7) 0.20
HDL (mmol/L) 1.11 (0.23) 1.13 (0.27) 0.80
LDL (mmol/L) 2.5 (0.6) 2.7 (0.6) 0.28
Triglyceride (mmol/L) 0.95 (0.24) 1.04 (0.34) 0.35
P-glucose (mmol/L) 4.7 (0.3) 4.8 (0.4) 0.41
S-insulin (pmol/L) 26 (10) 23 (14) 0.55
S-C-peptide (pmol/L) 441 (123) 441 (156) 0.98
Response during fasting
Energy expenditure (kJ/24 h) −46.1 (−2.8%) +85.6 (+5.1%) 0.02
S-insulin (pmol/L) −16.6 (−60%) −11.1 (−42%) 0.05
Triglyceride (mmol/L) −0.18 (−19.0%) −0.10 (−9.9%) 0.02
Data are means (SD). p values <0.05 are bold. Lipids, glucose and insulin/C-peptide were measured at 8.00 AM on day 1, after 12 h of fasting (in the fasting study).
HgbA1c was measured before the standardization period. Change in energy expenditure was calculated from after 12 h fasting until 31 h fasting. Changes in
insulin and triglyceride during fasting were calculated from after 12 h fasting until 34 and 36 h fasting, respectively. These results have previously been reported [27]
BMI body mass index, W/H ratio waist-hip ratio, Subtotal without the head, Lean without fat and bone
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In the mixed effects model, the residuals of p-leptin
were found to have a non-parametric distribution and
log transformation of p-leptin levels was therefore
performed. All statistical tests were performed at a
significance level of p ≤ 0.05, using SAS 9.4 software
(SAS Institute Inc., USA).
Results
Study subject characteristics
Clinical characteristics of both birth weight groups
during the 36-h fasting study have previously been
described [27] and are shown in Table 1.
Influence of fasting on LEP and ADIPOQ DNA methylation
in SAT
The degree of LEP and ADIPOQ DNA methylation was
positively correlated between the different CpG sites
within an assay, in each gene promoter (all p ≤ 0.04, re-
sults not shown). We therefore performed statistical
analysis of the average degree of DNA methylation
across all sites within each assay (Figs. 2, 3, and 4) as
well as for the individual CpG sites (Additional file 1:
Tables S2, S3, S4, and S5).
Among NBW subjects, the average degree of DNA
methylation increased significantly with 2.2% in the pro-
moter of LEP (assay 2, p = 0.04) and borderline signifi-
cantly with 3.9% in ADIPOQ (assay 2, p = 0.06), after 36 h
fasting compared to the control study (N = 8 + 8 NBW,
paired analysis) (Fig. 3a, b). In addition, at the individual
CpG sites, LEP DNA methylation increased ~5% with fast-
ing at sites −51 and −19 (p = 0.01, p = 0.03), and decreased
2.3% at site −250 (p = 0.007) (Additional file 1: Table S2).
For ADIPOQ, DNA methylation increased 5.4% with fast-
ing at site −327 among the NBW subjects (p = 0.007)
(Additional file 1: Table S3).
Among LBW subjects, on the contrary, no influence
of fasting was observed in either LEP or ADIPOQ DNA
methylation degree (N = 8 + 8 LBW, paired analysis)
(Fig. 3a, b, Additional file 1: Tables S2 and S3).
Influence of birth weight on LEP and ADIPOQ DNA
methylation in SAT
In the control study, LBW subjects presented 1.8%
higher average degree of LEP promoter DNA methyla-
tion (assay 1, p = 0.02) and 3.3% higher average degree of
ADIPOQ promoter DNA methylation (assay 2, p = 0.03)
compared to NBW subjects (N = 8 LBW versus 8 NBW,
unpaired analysis) (Fig. 4a). In addition, two individual
LEP CpG sites (−441, −393) displayed higher levels of
methylation among LBW subjects (Additional file 1:
Table S4). There were no differences in average or site-
specific DNA methylation of LEP assay 2 or ADIPOQ
assay 1 between NBW and LBW subjects in the control
study (Fig. 4a and Additional file 1: Tables S4 and S5).
After 36 h fasting, there were no differences in aver-
age degree of LEP or ADIPOQ DNA methylation be-
tween the two birth weight groups (N = 20 LBW versus
17 NBW, unpaired analysis) (Fig. 4b). Nevertheless, one
LEP CpG site (−519) displayed higher DNA methyla-
tion in LBW subjects compared to NBW subjects and
one LEP CpG unit (covering sites −74, −71, −62) dis-
played lower methylation degree in LBW subjects com-
pared to NBW subjects, after fasting (p = 0.02, p = 0.05,
Additional file 1: Table S4).
Fig. 2 Assay design. Overview of successfully analyzed CpG sites in LEP (a) and ADIPOQ (b) by EpiTYPER. For LEP, two EpiTYPER assays were
designed to cover the proximal LEP promoter region (Assay 1 and Assay 2). For ADIPOQ, one assay was designed to cover the distal enhancer
region (Assay 1) and one assay to cover a proximal promoter region (Assay 2). Due to base-specific cleavage, several CpG sites were analyzed as
units, as indicated with brackets. The binding sites for transcription factor C/EBP (CCAAT-enhancer-binding protein) (−55 to −44) and the TATA
box (−30 to −25) is marked on the LEP promoter (a)
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LEP and ADIPOQ gene expression in SAT before and after
fasting
Gene expression of LEP or ADIPOQ did not differ be-
tween NBW and LBW subjects in either the control or
fasting study (Fig. 5a, b). ADIPOQ expression levels in-
creased significantly after fasting among LBW subjects
(p = 0.04) but not among NBW subjects (Fig. 5c, d). No
significant changes in LEP gene expression were found
with fasting in either of the groups, but especially after
fasting a large individual variation was observed in the
LBW group (Fig. 5c, d).
Adipokine plasma profiles before and after fasting
At baseline, after the overnight fast of 12 h, p-leptin
levels were significantly higher among LBW subjects
compared to the NBW group (p = 0.05). After 36 h fast-
ing, both groups exhibited a more than threefold
decrease of p-leptin levels (p < 0.0001) (Fig. 6a). When
performing a mixed effects model of repeated measure-
ments of p-leptin levels during the entire intervention
study, the p-leptin effect over time was found to be
significantly different between the groups (p = 0.01).
No difference was found in p-leptin levels between the
groups after either the IVGTT or meal test, when
examined by mixed effects models. In addition, these
interventions did not appear to have any effect on p-
leptin levels, which remained low after the fasting chal-
lenge in both groups, though a slight and non-significant
increase was observed in both groups (Fig. 6a).
The fasting intervention did not affect p-adiponectin
levels in either of the groups, and no differences were
found in p-adiponectin levels between the groups at any
of the time points during the intervention study (Fig. 6b).
Associations between SAT LEP and ADIPOQ DNA
methylation and mRNA expression
Next, we investigated whether DNA methylation degree of
the LEP and ADIPOQ promoter was associated to gene ex-
pression levels in SAT. A significant positive correlation
was found between average LEP DNA methylation (assay
2) and mRNA expression only in the NBW group (p =
0.01) (Table 2). ADIPOQ DNA methylation in the proximal
promoter (assay 2) was inversely associated with mRNA
expression levels in both groups, with a borderline signifi-
cance when groups were combined (p = 0.07) (Table 2).
Associations between adiposity and SAT LEP and ADIPOQ
DNA methylation or plasma levels
Finally, we tested if LEP and ADIPOQ DNA methylation
and/or gene expression in SAT were associated to
a b
Fig. 3 Influence of fasting on DNA methylation of LEP (a) and ADIPOQ (b) in SAT from NBW and LBW men. Avr. average. N = 8 LBW, 8 NBW.
Comparisons by paired analyses between control and fasting study. Data are mean ± SD
a b
Fig. 4 Influence of birth weight on DNA methylation of LEP and ADIPOQ in SAT. a Control study: Avr. average. N = 8 LBW, 8 NBW. b Fasting study:
N = 20 LBW, 17 NBW. Comparisons by unpaired analyses between NBW and LBW subjects. Data are mean ± SD
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phenotype including the clinical characteristics of BMI,
total BF%, and plasma adipokine levels. LEP (assay 1 + 2)
and ADIPOQ (assay 1) DNA methylation was signifi-
cantly positively associated with total BF% (p < 0.05) but
not with BMI, when combining the groups (n = 37)
(Table 2). When performing correlation analysis by birth
weight group, only LBW subjects presented a positive
association between LEP DNA methylation and total
BF% (p ≤ 0.05), and only NBW subjects present a
positive association between ADIPOQ (assay 2) DNA
methylation and total BF% (p = 0.002).
We further evaluated the effect of adiposity on base-
line adipokine plasma levels (after 12 h fasting). In both
groups, positive correlations were found between p-
leptin levels and BMI or BF%, with the strongest associa-
tions observed in the NBW group for all variables
(Table 2). BMI and BF% showed significant negative
associations to p-adiponectin in the NBW group and in
both groups combined (p ≤ 0.005) (Table 2).
Discussion
To the best of our knowledge, fasting as an intervention
has not previously been investigated with regard to
effects on DNA methylation changes, either in animals
or in humans. This study shows that the promoter DNA
methylation of two metabolically important adipokine
genes, LEP and ADIPOQ, are affected by 36 h fasting in
SAT only in NBW subjects and not LBW subjects.
a
c
b
d
Fig. 5 Influence of birth weight (a, b) and fasting (c, d) on SAT LEP and ADIPOQ gene expression levels. Rel. relative. a Control study: N = 8 LBW, 8
NBW. b Fasting study: N = 20 LBW, 16 NBW, comparisons by unpaired analyses between NBW and LBW subjects. c, d N = 8 LBW, 7 NBW,
comparisons by paired analyses between control and fasting study. Data are mean ± SD
a b
Fig. 6 P-leptin (a) and p-adiponectin (b) levels before and after 36 h fasting in LBW and NBW subjects. N = 21 LBW, 18 NBW. Data are means ±
SEM. p-leptin levels were significantly higher among LBW subjects after 12 h of fasting (overnight fast) (p = 0.05). A threefold decrease of p-leptin
levels (p < 0.0001) was observed after fasting, with LBW subjects still characterized with non-significant higher p-leptin compared to the NBW
subjects. p-leptin levels were also significantly different regarding the slope of the curve between the two groups (p = 0.05)
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Furthermore, we show that LBW subjects have higher
baseline methylation degree (after overnight fast) of both
gene promoters investigated. However, our results do
not support that the promoter LEP and ADIPOQ DNA
methylation degree is directly involved in regulating
gene expression under a short-term fasting intervention.
The literature investigating effects of nutritional chal-
lenges on DNA methylation in humans is limited and in-
cludes studies addressing effects of high-calorie diets [6–9].
We have previously found that LBW subjects, when under-
going a high-fat feeding, exhibit less changeability in
muscle tissue DNA methylation than matched NBW con-
trols [33]. Together with our current findings showing that
only NBW subjects increase DNA methylation with fast-
ing, it leads us to speculate that LBW subjects may be
more inflexible in altering the DNA methylation status
when metabolically challenged. The extent to which such
metabolic inflexibility in terms of acute regulation of DNA
methylation may contribute to an increased risk of meta-
bolic disease in LBW subjects remains uncertain.
The shown changes in DNA methylation among NBW
subjects occurred mostly at CpG sites located closer to
the transcription start site, which was particularly prom-
inent in the LEP promoter. These results suggest that
the proximal LEP promoter region including the TATA
box (−30 to −25) and a transcription factor-binding site
for CCAAT-enhancer-binding proteins (C/EBP) (cover-
ing CpG −51), which previously was shown to be
important for regulation of gene expression in rat adipo-
cytes [34], is more receptive to changes and might be an
important region in epigenetic regulation. With respect
to the observed significant changes in DNA methylation,
it cannot be excluded that short-term diet or fasting-
induced methylation changes, in contrast to long-term
and more constitutive methylation changes, may repre-
sent some beneficial cellular effects as a part of a normal
physiological response to diet changes. For example,
short-term, fasting-induced methylation (and potentially
gene expression) changes of LEP could relate to a feed-
back mechanism to decrease the inhibiting effects of
leptin on appetite and stimulate the subject to seek
refeeding to compensate for the decreased nutrient
supply. Brøns et al. demonstrated that when subjected to
a 5-day high-fat diet, LBW subjects in contrast to NBW
subjects did not increase p-leptin levels [26]. The lacking
p-leptin response to high-fat diet may contribute to a
relatively lower induction of satiety in LBW subjects. In
the current study, we found a higher baseline level of p-
leptin among LBW subjects, which also may affect
satiety among the LBW men. Moreover, p-leptin
decreased with fasting in both birth weight groups.
Despite the decrease in p-leptin with fasting, which is
in agreement with previous findings in fasting humans
and animals [35–37], we found no effect of fasting on
LEP gene expression. Epigenetic influences on gene
expression have in several studies been proposed to be
involved in the pathogenesis of insulin resistance and
T2D [4, 10–12, 38, 39]. Indeed LEP gene expression has
been shown to be switched on by demethylation of spe-
cific CpG sites located in the proximal LEP promoter,
during the differentiation of adipocytes [30]. Inspired by
this study, we recently examined LEP DNA methylation
in differentiating adipocytes isolated from LBW and
NBW subjects, and found an increased LEP DNA
methylation and a decreased expression in mature adi-
pocytes from LBW subjects compared to NBW subjects,
further reinforcing the hypothesis that LBW subjects are
less capable of regulating leptin secretion [40]. The
decreased secretion of leptin in the differentiated adipo-
cytes is not consistent with the increased baseline levels
of p-leptin among the LBW men described in the present
work, but could be explained by an intrinsic functional
impairment in LBW adipocytes, causing a reduced leptin
secretion. This may be compensated by an increased
adiposity in vivo resulting in increased p-leptin levels. In
our current study, no significant differences were found in
BMI and BF%, but indeed this has been observed in previ-
ous studies of LBW subjects [6, 23].
Regarding adiponectin, previous studies have consist-
ently reported lower circulating adiponectin levels in
LBW subjects [41–43], but this association was not repli-
cated here, possibly due to the younger age and matched
study participants included in this study. An increase in
ADIPOQ gene expression levels was observed after fasting
among LBW subjects only. This was unexpected but could
relate to unknown compensatory mechanisms associated
to the fasting-induced insulin resistance. Only a few stud-
ies have previously investigated the effects of fasting on
ADIPOQ expression and the results are of contradictory
nature [44–47]. Nevertheless, we speculate that an in-
creased degree of DNA methylation during fasting may
contribute to the fasting-induced insulin resistance.
Recently BMI was reported to be associated with methy-
lation degree in SAT, suggesting that obesity may involve
pathological pathways that to some extent are epigeneti-
cally regulated [3]. In addition, Houde et al. reported that
DNA methylation levels of ADIPOQ in SAT were posi-
tively associated with BMI in severely obese patients [48].
In our study, total BF% was found to be positively associ-
ated with both LEP and ADIPOQ promoter methylation
in SAT. This further enforces that changes in SAT DNA
methylation patterns are associated with obesity and could
be involved in energy homeostasis, but to which degree
needs to be further studied. Interestingly, LBW subjects
had a higher average degree of DNA methylation in both
LEP and ADIPOQ compared to NBW subjects, in the
control study. In the same study cohort we also showed
that DNA methylation of the metabolic master regulator
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PPARGC1A was higher in the LBW compared to the
NBW subjects after 36 h fasting [27]. These results are in
line with a previous finding of increased LEP promoter
DNA methylation in blood from adult subjects whose
mothers were exposed to famine during the peri-
conceptional period [49].
In both birth weight groups, p-leptin level was posi-
tively associated with BMI and total BF%, corresponding
well with the theory and previous studies [14, 15]. Add-
itionally, although a significant negative correlation be-
tween plasma adiponectin levels and BMI only was
observed among the NBW subjects, negative relations
were shown at both body fat parameters in both groups.
Still, this could indicate that LBW subjects regulate adi-
ponectin levels differentially and not as directly associ-
ated to the amount of body fat, as NBW subjects.
There are limitations to this study, i.e., we use birth
weight as a “proxy” for fetal environment. Additionally,
we do not have data on the reasons for the low birth
weight, e.g., maternal smoking in pregnancy or parental
height and cannot exclude possible causes.
The methylation differences that we report here in SAT
are slightly smaller than we observed in our previous
study of PPARGC1A in muscle between LBW and NBW
men after fasting (4.5%) [27]. However, overall the magni-
tude of birth weight on DNA methylation seems to be
modest [9]. Furthermore, a 36-h fasting intervention is a
quite short time period, compared to a previous 6-month
exercise study where larger effects in DNA methylation
changes were observed [4]. Still, the magnitude of the
methylation differences we observe in the fasting study is
similar to the 5-day overfeeding study in both muscle [8]
and SAT [25]. Moreover, we are only studying two genes
and cannot exclude that other genes may show bigger dif-
ferences in DNA methylation between the birth weight
groups or with fasting. LBW is a risk factor for complex,
polygenic diseases including T2D and it is well established
that numerous genes with modest effect sizes in methyla-
tion changes contribute to this disease [11, 12]. However,
we cannot exclude that the DNA methylation measured
in our study could be affected by a stochastic variation in
methylation, as earlier suggested [50].
Conclusions
A short-time metabolic fasting challenge induced small
but significant changes in DNA methylation of the ADI-
POQ and LEP gene promoters in adipose tissue of young
men. The findings support results from a 5-day overfeed-
ing study, indicating that LBW subjects are less flexible in
their regulation of DNA methylation degree than NBW
subjects when challenged with metabolic interventions.
These differential epigenetic patterns present in LBW sub-
jects may contribute to disease development by malfunc-
tions in the metabolically important adipose tissue.
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